DOI QR코드

DOI QR Code

Prostate Cancer: A Hospital-Based Survival Study from Mumbai, India

  • Balasubramaniam, Ganesh (Department of Cancer Registry, Biostatistics & Epidemiology, Tata Memorial Hospital) ;
  • Talole, Sanjay (Department of Cancer Registry, Biostatistics & Epidemiology, Tata Memorial Hospital) ;
  • Mahantshetty, Umesh (Department of Radiation Oncology, Tata Memorial Hospital) ;
  • Saoba, Sushama (Department of Cancer Registry, Biostatistics & Epidemiology, Tata Memorial Hospital) ;
  • Shrivastava, Shyam (Department of Radiation Oncology, Tata Memorial Hospital)
  • Published : 2013.04.30

Abstract

Background: Prostate cancer is common in elderly men, especially in western countries, and incidences are rising in low-risk populations as well. In India, the age-standardized rates vary between registries. Under these circumstances we have estimated the survival of prostate cancer patients based on age, family history, diabetes, hypertension, tobacco habit, clinical extent of disease (risk group) and treatment received. Materials and Methods: The present retrospective study was carried out at the Tata Memorial Hospital (TMH), Mumbai, India. During years 1999-2002, some 850 prostate cancer cases, including 371 new cases, treated in TMH were considered as eligible entrants for the study. Five-year survival rates using actuarial and loss-adjusted (LAR) method were estimated. Results: The patient population was distributed uniformly over the three age groups. A larger proportion of the patients were diagnosed at 'metastatic stage' and hormone treatment was most common. 20% patients had history of diabetes and 40% with hypertension. The 5-year overall survival rate was 64%. Survival was 55%, 74% and 52% for '<59 years','60-69 years' and '>70 years' respectively. Non-diabetic (70%), hypertensive (74%), with family history (80%) of cancer, with localized-disease (91%) and treated with surgery, either alone or in combination, (91%) had better survival. Conclusions: The present study showed that prostate cancer patients with localized disease at diagnosis experience a better outcome. Local treatment with either surgery or radiation achieves a reasonable outcome in prostate cancer patients. A detailed study will help in understanding the prognostic indicators for survival especially with the newer treatment technologies available now.

References

  1. Berkson J, Gage RP (1950). Calculation of survival rates for cancer. Proc Staff Meet Mayo Clinic, 25, 270-86.
  2. Bratt O, Kristoffersson U, Olsson H, Lundgren R (1998). Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor. Eur Urol, 34, 19-24. https://doi.org/10.1159/000019672
  3. Altekruse SF, Kosary CL, Krapcho M, et al (2010). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
  4. Aprikian AG, Zhang ZF, Fair WR (1994). Prostate adenocarcinoma in men younger than 50 years. Cancer, 74, 1768-77. https://doi.org/10.1002/1097-0142(19940915)74:6<1768::AID-CNCR2820740620>3.0.CO;2-9
  5. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004). Diabetes mellitus as a predictor of cancer mortality in a large cohort of us adults. Am J Epidemiol, 159, 1160-7. https://doi.org/10.1093/aje/kwh161
  6. Dillman RO, Hafer R, Cox C, McClure SE (2011). Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer. Int J Radiat Oncol Biol Phys, 79, 719-23. https://doi.org/10.1016/j.ijrobp.2009.11.041
  7. Ferlay J, Shin HR, Bray F, et al (2008). GLOBOCAN, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan. iarc.fr.
  8. Ganesh B (1995). Effect of lost to follow-up in estimating survival rates. ACTA Universitatis, Ser A, Vol. 440,Tampere, Finland, (Ph.D. Thesis).
  9. Gronberg H, Damber JE, Jonsson H, Lenner P (1994). Patient age as a prognostic factor in prostate cancer. J Urol, 152, 892-5.
  10. Merglen A, Schmidlin F, Fioretta G, et al (2007). Short-and long-term mortality with localized prostate cancer. Arch Intern Med, 167, 1944-50. https://doi.org/10.1001/archinte.167.18.1944
  11. Mettlin CJ, Murphy GP, Cunningham MP, et al (1997). The national cancer data base report on race, age, and region variations in prostate cancer treatment. Cancer, 80, 1261-6. https://doi.org/10.1002/(SICI)1097-0142(19971001)80:7<1261::AID-CNCR10>3.0.CO;2-5
  12. NCRP (2007). Two-year Report of the population based cancer registries-2004-2005. National Cancer Registry Programme, Indian Council of Medical Research, Bangalore.
  13. Rodriguez C, Tatham LM, Thun MJ, Calle EE, Heath CW (1997). Jr Smoking and fatal prostate cancer in a large cohort of adult men. Am J Epidemiol, 145, 466-75. https://doi.org/10.1093/oxfordjournals.aje.a009129
  14. SWPHO (2008). Prostate cancer survival by stage: Analysis undertaken by South West Public Health Observatory.

Cited by

  1. Diabetes - Increased Risk for Cancers through Chromosomal Aberrations? vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4571
  2. Diabetes Mellitus and HbA1c Levels Associated with High Grade Prostate Cancer vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2555